F.O.T.D. , you should have your profits rolled it into PRAN
Still not too late IMHO, at all, because the market cap is only 170 million, but its starting to go bonkers. Take a look at the volume on PRAN Friday- nearly 3 million shares and up 17%.
They are now the worlds leader in a race to have a drug that works on Alzeimers disease, as well as Huntington's, and Parkinson's.
Apparently I'm in very good company over at PRAN. I do want to thank you for all your posts this past year. I have to tell you that your tip got me interested in TSRX and I made a bundle. I also rode SNTS up most of the way, but bailed a little early as I got freaked out by all the insider sales.
I appreciated the tip last month. I bought a small stake immediately simply based upon your posts over on the PRAN mb. It HAS gone bonkers since and, of course, I wish I had a bit more... That being said, for many reasons, I doubt it is the kind of company I will risk much on. It is still a long shot and I don't have a good feel for the science. It isn't the big fat pitch I look for.
Dementia is a hard nut to crack. Although the science behind PRAN looks more than plausible, unfortunately metal causation links to all kinds of mental disease has been the realm of crackpots for decades. I guess I have a bias. Also, the measures being used in the Ph 2s seem squishy.
I have enough of a stake that I will keep an eye on things down under. You will know I am more interested if I start posting over there. Do you have any other tips? I don't have any company I feel strongly about right now. I've been accumulating DRTX and CYTK the past month or two. I have a pretty large share of GHDX for longer term and a bit of TTPH. I imagine I'll be cash heavy for a while.
Great, glad to hear you took a small position FOTD. Perhaps as time goes on you will be willing to add. I'm a believer, especially so in AD for their drug as previous results showed substantially improved executive function and a reduction in a key biomarker for AD, and that was a very short term trial. The need is so very great (and there is essentially nothing available) that any sort of help PRAN's drug offers will IMO be pounced upon by FDA, and a P2 conditional approval while they run a P3 is not out of the question. I would not underestimate who one of the founders is either, Dr. Tanzi of Harvard/Mass Gen teaching school fame. He is THE MAN behind PRAN and probably one of the top 3 neurological disorder experts in the world.
Stay tuned its going to be a wild ride over there. Hehe, talk about risk reward on a biotech. They say AD alone is worth about $15 billion.
I've been looking @ that one also and if it turns out that control of copper in the brain is the problem causing Alzheimers it could be the drug we are looking for... If not.. it's worth a buck~
But right now there is a bunch of speculation driving that price!